The Roles of mTOR Complexes in Lipid Metabolism

Annual Review of Nutrition

Volumn 35, Issue 1, 2015, Pages 321-348

  Caron, Alexandre ^a   Richard, Denis ^a   Laplante, Mathieu ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Adipogenesis; Lipid metabolism; Lipogenesis; MTOR

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; STEROL REGULATORY ELEMENT BINDING PROTEIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; TRIACYLGLYCEROL;

ADIPOCYTE; CELL DIFFERENTIATION; FATTY ACID OXIDATION; HISTOGENESIS; HUMAN; LIPID HOMEOSTASIS; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; MAMMAL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; WHITE ADIPOSE TISSUE; ADIPOGENESIS; ANIMAL; DIET; EATING; HOMEOSTASIS; METABOLISM; NUTRITION; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

MAMMALIA;

ADIPOGENESIS; ANIMALS; DIET; EATING; HOMEOSTASIS; HUMANS; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; MULTIPROTEIN COMPLEXES; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEINS; TOR SERINE-THREONINE KINASES; TRIGLYCERIDES;

EID: 84937542416     PISSN: 01999885     EISSN: 15454312     Source Type: Book Series    
DOI: 10.1146/annurev-nutr-071714-034355     Document Type: Review

References (154)

1. Abu-Elheiga L,OhW, Kordari P, Wakil SJ. 2003. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. PNAS 100:10207-12
2. Aggarwal D, Fernandez ML, Soliman GA. 2006. Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in Guinea pigs. Metabolism 55:794-802
3. Bakan I, Laplante M. 2012. ConnectingmTORC1 signaling to SREBP-1 activation. Curr. Opin. Lipidol. 23:226-34
4. Bar-Peled L, Sabatini DM. 2014. Regulation of mTORC1 by amino acids. Trends Cell Biol. 24:400-6
5. Bar-Peled L, Schweitzer LD, Zoncu R, Sabatini DM. 2012. Ragulator is a GEF for the Rag GTPases that signal amino acid levels to mTORC1. Cell 150:1196-208
6. Bell A, Grunder L, Sorisky A. 2000. Rapamycin inhibits human adipocyte differentiation in primary culture. Obes. Res. 8:249-54
7. Bengoechea-AlonsoMT, Ericsson J. 2009. A phosphorylation cascade controls the degradation of active SREBP1. J. Biol. Chem. 284:5885-95
8. Bentzinger CF, Romanino K, Cloetta D, Lin S, Mascarenhas JB, et al. 2008. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. 8:411-24
9. Birsoy K, Festuccia WT, Laplante M. 2013. A comparative perspective on lipid storage in animals. J. Cell Sci. 126:1541-52
10. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, et al. 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369:756-58
11. Brown NF, Stefanovic-Racic M, Sipula IJ, Perdomo G. 2007. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metabolism 56:1500-7
12. Carnevalli LS, Masuda K, Frigerio F, Le Bacquer O, Um SH, et al. 2010. S6K1 plays a critical role in early adipocyte differentiation. Dev. Cell 18:763-74
13. Cawthorn WP, Scheller EL, MacDougald OA. 2012. Adipose tissue stem cells meet preadipocyte commitment: going back to the future. J. Lipid Res. 53:227-46
14. Chakrabarti P,EnglishT, Shi J, Smas CM,Kandror KV. 2010. Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. Diabetes 59:775-81
15. Chakrabarti P, Kim JY, SinghM, Shin YK, Kim J, et al. 2013. Insulin inhibits lipolysis in adipocytes via the evolutionarily conserved mTORC1-Egr1-ATGL-mediated pathway. Mol. Cell. Biol. 33:3659-66
16. Chang GR, Chiu YS, Wu YY, Chen WY, Liao JW, et al. 2009. Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. J. Pharmacol. Sci. 109:496-503
17. ChangGR, Wu YY, Chiu YS, ChenWY, Liao JW, et al. 2009. Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJmice. Basic Clin. Pharmacol. Toxicol. 105:188-98
18. Cho HJ, Park J, Lee HW, Lee YS, Kim JB. 2004. Regulation of adipocyte differentiation and insulin action with rapamycin. Biochem. Biophys. Res. Commun. 321:942-48
19. Cornu M, Oppliger W, Albert V, Robitaille AM, Trapani F, et al. 2014. Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21. PNAS 111:11592-99
20. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F,Mootha VK, Puigserver P. 2007.mTORcontrols mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450:736-40
21. Cybulski N, Polak P, Auwerx J, Ruegg MA, Hall MN. 2009. mTOR complex 2 in adipose tissue negatively controls whole-body growth. PNAS 106:9902-7
22. Dibble CC, Elis W, Menon S, Qin W, Klekota J, et al. 2012. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol. Cell 47:535-46
23. Dif N, Euthine V, Gonnet E, Laville M, Vidal H, Lefai E. 2006. Insulin activates human sterolregulatory-element-binding protein-1c (SREBP-1c) promoter through SRE motifs. Biochem. J. 400:179-88
24. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, et al. 2010. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39:171-83
25. Efeyan A, Comb WC, Sabatini DM. 2015. Nutrient-sensing mechanisms and pathways. Nature 517:302-10
26. El-Chaar D, Gagnon A, Sorisky A. 2004. Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase versus eIF4E-BP1. Int. J. Obes. Relat.Metab. Disord. 28:191-98
27. Festuccia WT, Pouliot P, Bakan I, Sabatini DM, Laplante M. 2014. Myeloid-specific Rictor deletion induces M1 macrophage polarization and potentiates in vivo pro-inflammatory response to lipopolysaccharide. PLOS ONE 9:e95432
28. Foretz M, Pacot C, Dugail I, Lemarchand P, Guichard C, et al. 1999. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol. Cell. Biol. 19:3760-68
29. Frias MA, Thoreen CC, Jaffe JD, SchroderW, Sculley T, et al. 2006. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 16:1865-70
30. Gagnon A, Lau S, Sorisky A. 2001. Rapamycin-sensitive phase of 3T3-L1 preadipocyte differentiation after clonal expansion. J. Cell. Physiol. 189:14-22
31. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, et al. 2009. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15:148-59
32. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, et al. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev. Cell 11:859-71
33. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, et al. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30:214-26
34. Hagiwara A, CornuM, CybulskiN, Polak P, Betz C, et al. 2012. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab. 15:725-38
35. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, et al. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177-89
36. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, et al. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213-23
37. HernandezTL, Sutherland JP, Wolfe P, Allian-Sauer M, CapellWH,et al. 2010. Lack of suppression of circulating free fatty acids and hypercholesterolemia during weight loss on a high-fat, low-carbohydrate diet. Am. J. Clin. Nutr. 91:578-85
38. Horton JD, Bashmakov Y, Shimomura I, Shimano H. 1998. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. PNAS 95:5987-92
39. Horton JD, Goldstein JL, BrownMS. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109:1125-31
40. Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, et al. 2010. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59:1338-48
41. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, et al. 2011. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332:1317-22
42. Hung CM, Calejman CM, Sanchez-Gurmaches J, Li H, Clish CB, et al. 2014. Rictor/mTORC2 loss in the Myf5 lineage reprograms brown fat metabolism and protects mice against obesity and metabolic disease. Cell Rep. 8:256-71
43. Inoki K, Li Y, Xu T, Guan KL. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17:1829-34
44. Inoki K, Li Y, Zhu T, Wu J, Guan KL. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:648-57
45. Inoki K, Zhu T, Guan KL. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-90
46. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, et al. 2006. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125-37
47. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, et al. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6:1122-28
48. Kaizuka T, Hara T, Oshiro N, Kikkawa U, Yonezawa K, et al. 2010. Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly. J. Biol. Chem. 285:20109-16
49. Kammoun HL, Chabanon H, Hainault I, Luquet S,Magnan C, et al. 2009. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J. Clin. Invest. 119:1201-15
50. Kenerson HL, Yeh MM, Yeung RS. 2011. Tuberous sclerosis complex-1 deficiency attenuates dietinduced hepatic lipid accumulation. PLOS ONE 6:e18075
51. Kersten S. 2001. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep. 2:282-86
52. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, et al. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163-75
53. Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, et al. 2003. GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor andmTOR. Mol. Cell 11:895-904
54. Kim E,Goraksha-Hicks P, Li L,Neufeld TP, Guan KL. 2008. Regulation of TORC1 by RagGTPases in nutrient response. Nat. Cell Biol. 10:935-45
55. Kim JB, Spiegelman BM. 1996.ADD1/SREBP1promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 10:1096-107
56. Kim JB, Wright HM, Wright M, Spiegelman BM. 1998. ADD1/SREBP1 activates PPARγ through the production of endogenous ligand. PNAS 95:4333-37
57. Kim JE, Chen J. 2004. Regulation of peroxisome proliferator-activated receptor-γ activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 53:2748-56
58. Kim K, Pyo S, Um SH. 2012. S6 kinase 2 deficiency enhances ketone body production and increases peroxisome proliferator-activated receptor alpha activity in the liver. Hepatology 55:1727-37
59. Kohn AD, Summers SA,BirnbaumMJ, Roth RA. 1996. Expression of a constitutively activeAkt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J. Biol. Chem. 271:31372-78
60. Koyanagi M, Asahara S, Matsuda T, Hashimoto N, Shigeyama Y, et al. 2011. Ablation of TSC2 enhances insulin secretion by increasing the number of mitochondria through activation of mTORC1. PLOS ONE 6:e23238
61. Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, Lawrence JC Jr. 2008. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances basal glycogen synthase activity. Mol. Cell. Biol. 28:61-70
62. Kumar A, Lawrence JC Jr, Jung DY, Ko HJ, Keller SR, et al. 2010. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes 59:1397-406
63. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, et al. 2012. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335:1638-43
64. Laplante M, Horvat S, Festuccia WT, Birsoy K, Prevorsek Z, et al. 2012. DEPTOR cell-autonomously promotes adipogenesis, and its expression is associated with obesity. Cell Metab. 16:202-12
65. Laplante M, Sabatini DM. 2009. mTOR signaling at a glance. J. Cell Sci. 122:3589-94
66. Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149:274-93
67. Laplante M, Sabatini DM. 2013. Regulation ofmTORC1 and its impact on gene expression at a glance. J. Cell Sci. 126:1713-19
68. Laplante M, Sell H, MacNaul KL, Richard D, Berger JP, Deshaies Y. 2003. PPAR-γ activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 52:291-99
69. Le Bacquer O, Petroulakis E, Paglialunga S, Poulin F, Richard D, et al. 2007. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J. Clin. Invest. 117:387-96
70. Lebrun-Julien F, Bachmann L, Norrmen C, TrotzmullerM,Kofeler H, et al. 2014. BalancedmTORC1 activity in oligodendrocytes is required for accurate CNS myelination. J. Neurosci. 34:8432-48
71. Lee KY, Russell SJ, Ussar S, Boucher J, Vernochet C, et al. 2013. Lessons on conditional gene targeting in mouse adipose tissue. Diabetes 62:864-74
72. Li S, Brown MS, Goldstein JL. 2010. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. PNAS 107:3441-46
73. Li S, Ogawa W, Emi A, Hayashi K, Senga Y, et al. 2011. Role of S6K1 in regulation of SREBP1c expression in the liver. Biochem. Biophys. Res. Commun. 412:197-202
74. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, et al. 2003. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. PNAS 100:3077-82
75. LiuX, YuanH,Niu Y, NiuW, Fu L. 2012. The role of AMPK/mTOR/S6K1 signaling axis in mediating the physiological process of exercise-induced insulin sensitization in skeletal muscle of C57BL/6 mice. Biochim. Biophys. Acta 1822:1716-26
76. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. 2005. Rheb binds and regulates the mTOR kinase. Curr. Biol. 15:702-13
77. Lopes PC, Fuhrmann A, Sereno J, Espinoza DO, Pereira MJ, et al. 2014. Short and long term in vivo effects of Cyclosporine A and Sirolimus on genes and proteins involved in lipid metabolism in Wistar rats. Metabolism 63:702-15
78. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. 2005. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121:179-93
79. Magun R, Burgering BM, Coffer PJ, Pardasani D, Lin Y, et al. 1996. Expression of a constitutively activated form of protein kinase B (c-Akt) in 3T3-L1 preadipose cells causes spontaneous differentiation. Endocrinology 137:3590-93
80. Manning BD,Tee AR, LogsdonMN,Blenis J,Cantley LC. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol. Cell 10:151-62
81. Martens K, Bottelbergs A, Baes M. 2010. Ectopic recombination in the central and peripheral nervous system by aP2/FABP4-Cre mice: implications for metabolism research. FEBS Lett. 584:1054-58
82. Matsuda M, Korn BS, Hammer RE, Moon YA, Komuro R, et al. 2001. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev. 15:1206-16
83. MauvoisinD,Rocque G, Arfa O, Radenne A, Boissier P, MounierC. 2007. Role of the PI3-kinase/mTor pathway in the regulation of the stearoyl CoA desaturase (SCD1) gene expression by insulin in liver. J. Cell Commun. Signaling 1:113-25
84. Menendez JA, Lupu R. 2007. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7:763-77
85. Menghini R, Marchetti V, Cardellini M, Hribal ML, Mauriello A, et al. 2005. Phosphorylation of GATA2 by Akt increases adipose tissue differentiation and reduces adipose tissue-related inflammation: a novel pathway linking obesity to atherosclerosis. Circulation 111:1946-53
86. Morrisett JD, Abdel-FattahG,Kahan BD. 2003. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant. Proc. 35:143-50S
87. Nakae J,KitamuraT,KitamuraY,BiggsWH3rd, Arden KC, Accili D. 2003. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev. Cell 4:119-29
88. Narayanan SP, Flores AI, Wang F, Macklin WB. 2009. Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J. Neurosci. 29:6860-70
89. NobukuniT, JoaquinM, Roccio M, Dann SG,Kim SY, et al. 2005. Amino acidsmediatemTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. PNAS 102:14238-43
90. Norrmen C, Figlia G, Lebrun-Julien F, Pereira JA, Trotzmuller M, et al. 2014. mTORC1 controls PNS myelination along the mTORC1-RXRgamma-SREBP-lipid biosynthesis axis in Schwann cells. Cell Rep. 9:646-60
91. Norrmen C, Suter U. 2013. Akt/mTOR signalling in myelination. Biochem. Soc. Trans. 41:944-50
92. Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, et al. 2002. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. PNAS 99:11482-86
93. Owen JL, Zhang Y, Bae SH, Farooqi MS, Liang G, et al. 2012. Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase. PNAS 109:16184-89
94. Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, et al. 2008. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell 29:541-51
95. Pearce LR, Huang X, Boudeau J, Pawlowski R,Wullschleger S, et al. 2007. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J. 405:513-22
96. Pearce LR, Sommer EM, Sakamoto K, Wullschleger S, Alessi DR. 2011. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochem. J. 436:169-79
97. Peng T, Golub TR, Sabatini DM. 2002. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell. Biol. 22:5575-84
98. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, et al. 2003. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 17:1352-65
99. PereiraMJ, Palming J, Rizell M, AurelianoM, Carvalho E, et al. 2013. The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue. Mol. Cell. Endocrinol. 365:260-69
100. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, et al. 2009. DEPTOR is an mTOR inhibitor frequently overexpressed inmultiplemyeloma cells and required for their survival. Cell 137:873-86
101. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, et al. 2011. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146:408-20
102. Polak P, Cybulski N, Feige JN, Auwerx J, Ruegg MA, Hall MN. 2008. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab. 8:399-410
103. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, et al. 2008. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8:224-36
104. Potter CJ, Pedraza LG, Xu T. 2002. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4:658-65
105. Reue K. 2009. The lipin family: mutations and metabolism. Curr. Opin. Lipidol. 20:165-70
106. Romanino K, Mazelin L, Albert V, Conjard-Duplany A, Lin S, et al. 2011. Myopathy caused by mammalian target of rapamycin complex 1 (mTORC1) inactivation is not reversed by restoring mitochondrial function. PNAS 108:20808-13
107. Rosen ED, MacDougald OA. 2006. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 7:885-96
108. Rosen ED, Spiegelman BM. 2014. What we talk about when we talk about fat. Cell 156:20-44
109. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. 2004. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. PNAS 101:13489-94
110. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. 1994. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78:35-43
111. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. 2010. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141:290-303
112. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, et al. 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320:1496-501
113. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, et al. 2007. PRAS40 is an insulinregulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25:903-15
114. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, et al. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14:1296-302
115. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, et al. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22:159-68
116. Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. 2010. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 468:1100-4
117. ShenWJ, Patel S,Natu V,Kraemer FB. 1998. Mutational analysis of structural features of rat hormonesensitive lipase. Biochemistry 37:8973-79
118. Shende P, Plaisance I, Morandi C, Pellieux C, Berthonneche C, et al. 2011. Cardiac raptor ablation impairs adaptive hypertrophy, altersmetabolic gene expression, and causes heart failure in mice. Circulation 123:1073-82
119. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, BrownMS, Goldstein JL. 1999. Insulin selectively increases SREBP-1cmRNA in the livers of rats with streptozotocin-induced diabetes. PNAS 96:13656-61
120. Shiota C, Woo JT, Lindner J, Shelton KD, Magnuson MA. 2006. Multiallelic disruption of the rictor gene in mice reveals thatmTORcomplex 2 is essential for fetal growth and viability. Dev. Cell 11:583-89
121. Sipula IJ, Brown NF, Perdomo G. 2006. Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation. Metabolism 55:1637-44
122. Soliman GA, Acosta-Jaquez HA, Fingar DC. 2010. mTORC1 inhibition via rapamycin promotes triacylglycerol lipolysis and release of free fatty acids in 3T3-L1 adipocytes. Lipids 45:1089-100
123. Stylianou IM, Clinton M, Keightley PD, Pritchard C, Tymowska-Lalanne Z, et al. 2005. Microarray gene expression analysis of the Fob3b obesityQTLidentifies positional candidate gene Sqle and perturbed cholesterol and glycolysis pathways. Physiol. Genomics 20:224-32
124. Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, et al. 2005. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCFFbw7. Cell Metab. 1:379-91
125. Tee AR, Manning BD,Roux PP, Cantley LC, Blenis J. 2003. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13:1259-68
126. Thedieck K, Polak P, Kim ML, Molle KD, Cohen A, et al. 2007. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLOS ONE 2:e1217
127. Toh SY, Gong J, Du G, Li JZ, Yang S, et al. 2008. Up-regulation of mitochondrial activity and acquirement of brown adipose tissue-like property in the white adipose tissue of fsp27 deficient mice. PLOS ONE 3:e2890
128. Tontonoz P, Spiegelman BM. 2008. Fat and beyond: the diverse biology of PPARγ. Annu. Rev. Biochem. 77:289-312
129. Um SH, Frigerio F,Watanabe M, Picard F, Joaquin M, et al. 2004. Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200-5
130. VanderHaar E, Lee SI, Bandhakavi S, Griffin TJ,Kim DH. 2007. Insulin signalling tomTORmediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9:316-23
131. Wan M, Leavens KF, Saleh D, Easton RM, Guertin DA, et al. 2011. Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c. Cell Metab. 14:516-27
132. Wang BT, Ducker GS, Barczak AJ, Barbeau R, Erle DJ, Shokat KM. 2011. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. PNAS 108:15201-6
133. Wang L, Harris TE, Roth RA, Lawrence JC Jr. 2007. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J. Biol. Chem. 282:20036-44
134. Wang QA, Scherer PE. 2014. The AdipoChasermouse: amodel tracking adipogenesis in vivo. Adipocyte 3:146-50
135. Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, et al. 2001. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J. Clin. Invest. 107:1263-73
136. Yabe D, Komuro R, Liang G, Goldstein JL, Brown MS. 2003. Liver-specific mRNA for Insig-2 downregulated by insulin: implications for fatty acid synthesis. PNAS 100:3155-60
137. Yahagi N, Shimano H, Hasty AH, MatsuzakaT, Ide T, et al. 2002. Absence of sterol regulatory elementbinding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lepob/Lepob mice. J. Biol. Chem. 277:19353-57
138. Yang J, Goldstein JL, Hammer RE, Moon YA, BrownMS, Horton JD. 2001. Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene. PNAS 98:13607-12
139. Yao Y, Suraokar M, Darnay BG, Hollier BG, Shaiken TE, et al. 2013. BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. Sci. Signal. 6:ra2
140. Ye L, Varamini B, Lamming DW, Sabatini DM, Baur JA. 2012. Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2. Front. Genet. 3:177
141. Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, et al. 2011. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 14:21-32
142. YehWC, Bierer BE, McKnight SL. 1995. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. PNAS 92:11086-90
143. Yellaturu CR, Deng X, Cagen LM, Wilcox HG, Mansbach CM 2nd, et al. 2009. Insulin enhances post-translational processing of nascent SREBP-1c by promoting its phosphorylation and association with COPII vesicles. J. Biol. Chem. 284:7518-32
144. Yellaturu CR, Deng X, Park EA, Raghow R, Elam MB. 2009. Insulin enhances the biogenesis of nuclear sterol regulatory element-binding protein (SREBP)-1c by posttranscriptional down-regulation of Insig-2A and its dissociation from SREBP cleavage-activating protein (SCAP) SREBP-1c complex. J. Biol. Chem. 284:31726-34
145. Yoon MS, Zhang C, Sun Y, Schoenherr CJ, Chen J. 2013. Mechanistic target of rapamycin controls homeostasis of adipogenesis. J. Lipid Res. 54:2166-73
146. Yu W, Chen Z, Zhang J, Zhang L, Ke H, et al. 2008. Critical role of phosphoinositide 3-kinase cascade in adipogenesis of human mesenchymal stem cells. Mol. Cell. Biochem. 310:11-18
147. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, et al. 2011. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332:1322-26
148. Yuan M, Pino E, Wu L, Kacergis M, Soukas AA. 2012. Identification of Akt-independent regulation of hepatic lipogenesis bymammalian target of rapamycin (mTOR) complex 2. J. Biol. Chem. 287:29579-88
149. Zechner R, Zimmermann R, Eichmann TO, Kohlwein SD, Haemmerle G, et al. 2012. FAT SIGNALS-lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 15:279-91
150. Zhang HH, Huang J, Duvel K, Boback B, Wu S, et al. 2009. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLOS ONE 4:e6189
151. Zinzalla V, Stracka D, Oppliger W, Hall MN. 2011. Activation of mTORC2 by association with the ribosome. Cell 144:757-68
152. Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM. 2011. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H+-ATPase. Science 334:678-83
153. Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12:21-35
154. Zou J, Zhou L, Du XX, Ji Y, Xu J, et al. 2011. Rheb1 is required for mTORC1 and myelination in postnatal brain development. Dev. Cell 20:97-108